# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Etzer Darout initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target...
Guggenheim analyst Yatin Suneja maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $101 to $150.
BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $112 to $120.
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no ne...
Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused o...
50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met...